drugset / Trial / NCT03390647

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics in Healthy Adult Male Participants

NCT03390647 ↗

Phase 1 Withdrawn EA Pharma Co., Ltd.
RandomizedParallel-groupTriple-blindBasic science

Summary

The primary purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of multiple oral doses of E6130 in Japanese healthy adult male participants.

Timeline

Start
2017-12-21
Primary completion
2019-03
Completion
2019-03

Outcome

Outcome not reported

Stopped: “Decision of Sponsor”

Drugs

EvaluationDrugModalityDoseRoute
Subject E6130 Unknown — Oral

Indications

No indication recorded.